Nathan H. Fowler, MD, MD Anderson Cancer Center

Articles

ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas

January 22nd 2021

ASH 2020 Updates in Non-CLL B-Cell Lymphomas

January 22nd 2021

ASH 2020 Updates in CLL

January 22nd 2021

Treatment of R/R DLBCL: Beyond CAR T Therapy

September 22nd 2020

Phase 2B SADAL Trial in R/R DLBCL

September 22nd 2020

RE-MIND Study in R/R DLBCL

September 22nd 2020

L-MIND Study in R/R DLBCL

September 22nd 2020

CAR T in Transplant-Eligible and Transplant-Ineligible DLBCL

September 22nd 2020

Standard of Care for Relapsed/Refractory DLBCL

September 22nd 2020

Closing Thoughts on Treatment of R/R DLBCL

July 15th 2020

Improving Outcomes in Patients With R/R DLBCL

July 15th 2020

Emerging Therapies for R/R DLBCL

July 15th 2020

Safety and Efficacy of Oral Agents in R/R DLBCL

July 15th 2020

Treatment of R/R DLBCL: CD19-Directed Therapy vs CAR T

July 15th 2020

CD19-Directed Therapies for Treatment of R/R DLBCL

July 15th 2020

CAR T in R/R DLBCL: Safety and Patient Selection

July 15th 2020

ASCO 2020 Data: CAR T in R/R DLBCL

July 15th 2020

Role of CAR T-cell Therapy in R/R DLBCL

July 15th 2020

Treatment in Transplant-ineligible R/R DLBCL

July 15th 2020

Prognosis of R/R DLBCL

July 15th 2020